Advancis’ Last Try For Pulsys Platform? New Phase III Trial To Start In November
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Advancis is prepared to begin a new Phase III trial of its Pulsys pulsatile amoxicillin formulation in November in hopes of following through with its previously planned NDA
You may also be interested in...
Advancis Pulsys platform gets second try
Advancis is moving ahead with another Phase III trial of its Pulsys pulsatile formulation of amoxicillin, the firm says Nov. 3. After a pre-Phase III meeting with FDA to discuss the 600-patient trial, the firm says it is on track to submit a 505(b)(2) NDA for treatment of adults and adolescents with strep throat in "late 2006." The two-arm trial will compare a 10-day regimen of once-daily amoxicillin Pulsys to penicillin VK dosed four times daily. Advancis previously indicated that the new trial could be its last chance to prove the viability of the Pulsys technology. The amoxicillin formulation previously failed to show statistical non-inferiority to penicillin in two Phase III studies (1Pharmaceutical Approvals Monthly October 2005, p. 8)...
Par/Advancis Pulsatile Amoxicillin Filing Plans On Hold After Phase III Failure
A potential NDA submission for Advancis' Pulsys pulsatile amoxicillin formulation will be delayed at least until late 2006 following failure of a Phase III trial to show statistical non-inferiority to penicillin
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011